Autoimmune Disease
Grant Program

Deadline Extended!
Submit by April 14, 2024

Do you have a project that would benefit from a comprehensive analysis of inflammation biomarkers with best-in-class sensitivity?

Alamar’s Autoimmune Grant Program will award three (3) research projects with analysis using the NULISAseq Inflammation Panel 250 through Alamar’s Technology Access Program 

  • 1st Place Prize: Analysis of 344 samples  
  • 2nd Place Prize: Analysis of 172 samples  
  • 3rd Place Prize: Analysis of 86 samples 
inflammation panel detectability in plasma

The NULISAseq™ Inflammation Panel 250 provides the sensitivity to detect changes in the most important protein biomarkers in biofluids at attomolar (fg/mL) levels. This comprehensive view of inflammation enables applications that span from basic discovery to clinical development. Potential Research Applications Include: 

  • Disease Pathogenesis: Elucidate mechanisms of inflammation and identify potential therapeutic targets. By measuring multiple proteins simultaneously, gain insights into complex interactions, signaling pathways, and regulatory mechanisms involved in disease processes. 
  • Biomarker Discovery: Identify new biomarkers associated with inflammation by measuring a wide range of proteins simultaneously in different disease states and compare them to healthy controls. 
  • Drug Development and Clinical Trials: Evaluate the effects of potential therapeutic agents on specific protein targets related to inflammation and assess their efficacy in preclinical and clinical studies. 
  • Diagnostic Development: Measure specific protein markers known to be associated with the presence and severity of diseases and differentiate between different subtypes or stages of a particular disease. 

*Terms and Conditions apply

APPLY BY APRIL 14, 2024!

Terms and Conditions

Award Selection Criteria:

  • Human disease with unmet need for fluid-based biomarkers  
  • Access to banked samples with associated clinical annotations 
  • Ability to complete project within a 6-month period 
  • Potential to publish the results on high impact factors as determined by the judges 
  • Grant submissions must be received by 11:59 PM Pacific Time on Sunday, April 14, 2024. 

Publication of Results: 
All grant submissions are confidential to the individual submitter and will not be published or distributed. Upon project completion, the grant winner agrees to participate in one of the following activities relating to the specific project, with specific details of the applicable activity to be mutually agreed upon in good faith by Alamar and the winner: local seminar, webinar, case study, blog post, or poster presentation. Each winner agrees that Alamar shall have the right to use de-identified data from the winner’s project in application notes or marketing literature.

Eligibility and Requirements:
In order to be eligible to win the grant of the NULISAseq™ Inflammation Panel 250, applicants must be actively enrolled at an academic institution or employed at a research facility in a capacity in which they are able to perform research on and have capabilities to collect samples as well as run their project as described in the submitted abstract. The grant winner must be age 18 or older. Members of the immediate families of Alamar employees and directors, and persons living in the same household as such persons, are ineligible for this grant. 

Alamar Biosciences, Inc. is the sponsor of this Autoimmune Disease Grant Program.  No purchase is necessary to enter.  By applying for the grant, each applicant agrees to these terms and conditions and that Alamar may process the personal data he or she provides in accordance with Alamar’s privacy policies available at This grant program is void where prohibited or otherwise restricted by law. The grant winner or its applicable institution is responsible for any tax liability incurred by accepting the services provided.  This is not a “cash in hand” grant and the grant winner has no option to receive any cash payment or alternative award in lieu of the offered services. The grant may not be transferred or assigned. The services, if any, will be provided subject to Alamar’s standard terms and conditions related to TAP service projects, as the same may be amended from time to time. Alamar has not made any warranty, representation, or guarantee, express or implied, with respect to the grant, including, without limitation, the provided service’s quality or fitness for a particular purpose.  Alamar reserves the right in its sole discretion to cancel, modify or suspend the grant program. These terms and conditions and any action related to this grant program are governed by the laws of the State of Delaware, USA, without regard to its conflict of law provisions.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.